$40.53
+0.87 (+2.19%)
Open$40.37
Previous Close$39.66
Day High$41.44
Day Low$39.66
52W High$44.00
52W Low$14.00
Volume—
Avg Volume58.3K
Market Cap154.57M
P/E Ratio—
EPS$-3.34
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
-17.2% upside
Current
$40.53
$40.53
Target
$33.56
$33.56
$24.17
$33.56 avg
$46.23
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 687.2K | 1.09M | 10.43M |
| Net Income | -12,476,417 | -17,738,981 | 2.46M |
| Profit Margin | -1,815.3% | -1,724.6% | 23.6% |
| EBITDA | -16,273,435 | -24,423,006 | 3.49M |
| Free Cash Flow | — | — | 3.25M |
| Rev Growth | -36.7% | -36.7% | +12.7% |
| Debt/Equity | — | — | 1.45 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |